Lymphoma ASH 22

Chadi Nabhan, MD, MBA, FACPMantle Cell Lymphoma | January 10, 2023
Tycel Phillips, MD, of the City of Hope, talks about the TRIANGLE study and frontline therapy in mantle cell lymphoma.
View More
Cecilia BrownMeeting News | January 10, 2023
Neha Mehta-Shah, MD, MSCI, discusses bispecific antibodies in B-cell lymphomas.
Cecilia BrownAggressive B-Cell Lymphoma | December 15, 2022
The phase II ELM-2 study showed odronextamab had “meaningful clinical efficacy” in patients with relapsed/refractory ...
Advertisement
Leah SherwoodMeeting News | December 14, 2022
Advances in treatment have led to improved outcomes in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Leah SherwoodMeeting News | February 22, 2023
Age and diagnosis were key predictors of whether a patient with non-Hodgkin lymphoma would participate in a clinical trial.
Leah SherwoodMeeting News | December 12, 2022
A novel risk estimate scale that can be used to measure survival in patients with non-Hodgkin lymphoma has been proposed.
Advertisement
Cecilia BrownMeeting News | January 11, 2023
Giovanni Manfredi Assanto discusses research on anti-SARS-CoV-2 monoclonal antibodies in patients with lymphoma and COVID-19.
Kerri FitzgeraldHodgkin Lymphoma | December 10, 2022
The REALYSA study has garnered an enrollment rate of 54%—higher than typical clinical trial inclusion rates.
Leah LawrenceMeeting News | December 10, 2022
Survivors of lymphoma are at risk for the development of a second primary malignancy, including new lymphomas.
Leah LawrenceMeeting News | December 10, 2022
The bispecific antibody odronextamab had “compelling” efficacy in patients with relapsed or refractory follicular ...
Leah SherwoodAggressive B-Cell Lymphoma | December 10, 2022
A real-world study showed R-DA-EPOCH is “highly effective regimen” to treat primary mediastinal large B-cell lymphoma.
Cecilia BrownMeeting News | December 10, 2022
Ukrainians newly diagnosed with lymphoma have experienced a “dramatic” decrease in access to specialized care since the ...
Leah LawrenceMeeting News | December 8, 2022
Selinexor plus rituximab, gemcitabine, cisplatin and dexamethasone had encouraging activity in patients with B-cell lymphoma.
Advertisement
Advertisement
Editorial Board